Data Insights

Imifoplatin by Promontory Therapeutics for Thymoma (Thymic Epithelial Tumor): Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor). According to...

Data Insights

Imifoplatin by Promontory Therapeutics for Pancreatic Cancer: Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

Imifoplatin by Promontory Therapeutics for Ovarian Cancer: Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Data Insights

Imifoplatin by Promontory Therapeutics for Ovarian Cancer: Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Imifoplatin in Ovarian Cancer

Data Insights

Imifoplatin by Promontory Therapeutics for Pancreatic Cancer: Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Imifoplatin in Pancreatic Cancer

Data Insights

Imifoplatin by Promontory Therapeutics for Thymoma (Thymic Epithelial Tumor): Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Imifoplatin in Thymoma (Thymic Epithelial Tumor)

Data Insights

Imifoplatin by Promontory Therapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Imifoplatin in Squamous Non-Small Cell Lung Cancer

Data Insights

Imifoplatin by Promontory Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Imifoplatin in Bile Duct Cancer (Cholangiocarcinoma)